Live Science on MSN14h
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Medscape3d
Introduction to the New Prescription Drug Labeling by the Food and Drug Administration
The revised prescription drug labeling developed by the Food and Drug Administration (FDA) is described. Summary: A new FDA final rule, "Requirements on Content and Format of Labeling for Human ...
JD Supra6d
End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists
On January 7, 2025, the US Food and Drug Administration (FDA) issued two parallel guidance documents for the Section 503A and Section 503B bulk ...
The FDA just approved a new painkiller. Is it too good to be true?
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
JD Supra3d
Finally, FDA’s Final Word on Unapproved Use Communications
On January 7, 2025, the U.S. Food and Drug Administration (“FDA” or “Agency”) released a long-awaited guidance titled, “Communications From Firms ...
Arizona Mirror6d
Legal briefs challenge Arizona’s lethal injection drugs as illegal
Medical experts and death row inmates file legal briefs challenging legality of Arizona's execution drugs ahead of March ...
Protesters rally against proposed legal shield for pesticide makers at Iowa Capitol
Bayer disputes the cancer claims, and the EPA has said the product is not likely to be carcinogenic to humans when used as ...
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...